Rika Yamada1,2, Akihiro Nishida3,4, Masataka Shimozono1,2, Takanori Kameda1,2, Noriko Miyamoto1,2, Michiko Mandai1,5, Yasuo Kurimoto1,2. 1. Department of Ophthalmology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. 2. Department of Ophthalmology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. 3. Department of Ophthalmology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. aki_n@kcho.jp. 4. Department of Ophthalmology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. aki_n@kcho.jp. 5. Laboratory for Retinal Regeneration, Center for Developmental Biology, RIKEN, 2-2-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
Abstract
PURPOSE: Our aim was to investigate predictive factors associated with efficacy and recurrence after intravitreal bevacizumab (IVB) therapy for macular edema (ME) in patients with branch retinal vein occlusion (BRVO). METHODS: Fifty-two eyes of 52 patients who underwent IVB as a primary treatment against ME associated with BRVO were included retrospectively. Based on the postoperative central retinal thickness (CRT), the patients were classified into two groups: an effective group in which the CRT decreased to ≤250 µm within postoperative 3 months and an ineffective group in which the CRT remained >250 µm throughout the first 3 months. The effective group was then divided into two subgroups: a recurrent group in which ME had once resolved but recurred afterward, and a nonrecurrent group in which the resolution of ME was maintained throughout the follow-up period without additional injections. Preoperative factors such as age, gender, estimated elapsed time from disease onset to IVB, visual acuity, and CRT were compared between groups. RESULTS: There was no significant difference between effective (n = 37) and ineffective (n = 15) groups in all preoperative factors. Between recurrent (n = 26) and nonrecurrent (n = 11) groups, elapsed time was significantly different (29.7 ± 29.5 vs. 15.7 ± 8.9 weeks, respectively; P = 0.036), and there were no significant differences in the remaining factors. CONCLUSIONS: Early IVB treatment against BRVO may suppress ME recurrence.
PURPOSE: Our aim was to investigate predictive factors associated with efficacy and recurrence after intravitreal bevacizumab (IVB) therapy for macular edema (ME) in patients with branch retinal vein occlusion (BRVO). METHODS: Fifty-two eyes of 52 patients who underwent IVB as a primary treatment against ME associated with BRVO were included retrospectively. Based on the postoperative central retinal thickness (CRT), the patients were classified into two groups: an effective group in which the CRT decreased to ≤250 µm within postoperative 3 months and an ineffective group in which the CRT remained >250 µm throughout the first 3 months. The effective group was then divided into two subgroups: a recurrent group in which ME had once resolved but recurred afterward, and a nonrecurrent group in which the resolution of ME was maintained throughout the follow-up period without additional injections. Preoperative factors such as age, gender, estimated elapsed time from disease onset to IVB, visual acuity, and CRT were compared between groups. RESULTS: There was no significant difference between effective (n = 37) and ineffective (n = 15) groups in all preoperative factors. Between recurrent (n = 26) and nonrecurrent (n = 11) groups, elapsed time was significantly different (29.7 ± 29.5 vs. 15.7 ± 8.9 weeks, respectively; P = 0.036), and there were no significant differences in the remaining factors. CONCLUSIONS: Early IVB treatment against BRVO may suppress ME recurrence.
Authors: L L Lim; N Cheung; J J Wang; F M A Islam; P Mitchell; S M Saw; T Aung; T Y Wong Journal: Br J Ophthalmol Date: 2008-08-06 Impact factor: 4.638
Authors: Raafay Sophie; Gulnar Hafiz; Adrienne W Scott; Ingrid Zimmer-Galler; Quan Dong Nguyen; Howard Ying; Diana V Do; Sharon Solomon; Akrit Sodhi; Peter Gehlbach; Elia Duh; David Baranano; Peter A Campochiaro Journal: Am J Ophthalmol Date: 2013-10 Impact factor: 5.258
Authors: Chirag P Shah; Sunir J Garg; James F Vander; Gary C Brown; Richard S Kaiser; Julia A Haller Journal: Ophthalmology Date: 2011-06-25 Impact factor: 12.079
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li Journal: Ophthalmology Date: 2011-07-20 Impact factor: 12.079
Authors: Santi Maria Recupero; Andrea Perdicchi; G L Scuderi; Stefano Amodeo; Edoardo Maria Medori; Antonella Leonardi Journal: Ann Ophthalmol (Skokie) Date: 2006